Lilly ' s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

INDIANAPOLIS, Nov. 9, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company ' s (NYSE: LLY) investigational neutralizing antibody bamlanivimab...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials